Neopharmed Gentili S.P.A, founded in 1885 and located in Italy, is a prominent player in the pharmaceutical industry, dedicated to the research, development, and manufacturing of innovative healthcare solutions. The company specializes in the production of prescription drugs, over-the-counter medications, and various healthcare products, catering to diverse therapeutic areas.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| NEGENT 0.00% 2033-06-29 EURNeopharmed Gentili S.P.A | Italy | 2033-06-29 | 0.000 | 6.65 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Neopharmed Gentili began its bond issuance in the early 2000s, aiming to support its expansion and enhance its financial stability. A notable issuance occurred in 2015, when the company launched a €100 million bond with a fixed coupon rate of 3.5%, which attracted significant interest from investors. Currently, the yields on their bonds remain competitive compared to industry averages, with some unique features such as convertible options that add flexibility for investors. Recent news highlights their commitment to sustainability, as they announced plans to issue green bonds to finance eco-friendly initiatives.